Skip to content

Minerva Neurosciences, Inc.: 10-Q filed 2024-08-06

What Minerva Neurosciences, Inc. reported in its quarterly report filed 2024-08-06 (fiscal Q2 2024): 27 published measures, 78 facts as tagged in accession 0000950170-24-091195.

This filing

Form
10-Q (quarterly report)
Filed
2024-08-06
Fiscal period
fiscal Q2 2024
Accession
0000950170-24-091195 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Minerva Neurosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-06-3046,290,837USD
At 2023-12-3156,899,750USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-06-3090,782,452USD
At 2023-12-3185,357,240USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-06-30-44,491,615USD
At 2024-03-31-36,587,446USD
At 2023-12-31-28,457,490USD
At 2023-06-30-12,510,901USD
At 2023-03-31-26,618,172USD
At 2022-12-31-20,024,219USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-06-3030,881,000USD
At 2023-12-3140,912,575USD
At 2023-06-3051,796,711USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-8,233,487USD91
2024-01-01 to 2024-06-30-16,802,292USD182
2024-01-01 to 2024-03-31-8,568,805USD91
2023-04-01 to 2023-06-30-6,192,036USD91
2023-01-01 to 2023-06-30-13,162,448USD181
2023-01-01 to 2023-03-31-6,970,412USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-10,031,575USD182
2023-01-01 to 2023-06-30-3,987,287USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-3019,690,392USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-06-300USD182
2023-01-01 to 2023-06-300USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-06-30-413,617,720USD
At 2023-12-31-396,815,428USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-04-01 to 2024-06-307,568,981shares91
2024-01-01 to 2024-06-307,568,981shares182
2023-04-01 to 2023-06-305,511,163shares91
2023-01-01 to 2023-06-305,426,150shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-04-01 to 2024-06-307,568,981shares91
2024-01-01 to 2024-06-307,568,981shares182
2023-04-01 to 2023-06-305,511,163shares91
2023-01-01 to 2023-06-305,426,150shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-1.09USD/shares91
2024-01-01 to 2024-06-30-2.22USD/shares182
2023-04-01 to 2023-06-30-1.12USD/shares91
2023-01-01 to 2023-06-30-2.43USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-1.09USD/shares91
2024-01-01 to 2024-06-30-2.22USD/shares182
2023-04-01 to 2023-06-30-1.12USD/shares91
2023-01-01 to 2023-06-30-2.43USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-06-308,163USD
At 2023-12-3110,884USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-06-30768,167USD182
2023-01-01 to 2023-06-30985,374USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-6,277,568USD91
2024-01-01 to 2024-06-30-12,959,531USD182
2023-04-01 to 2023-06-30-4,519,995USD91
2023-01-01 to 2023-06-30-9,868,513USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-06-3031,409,018USD
At 2023-12-3142,002,440USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-06-304,203,406USD
At 2023-12-313,340,417USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-06-30828,345USD
At 2023-12-311,805,320USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2024-06-3014,869,399USD
At 2023-12-3114,869,399USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-04-01 to 2024-06-306,277,568USD91
2024-01-01 to 2024-06-3012,959,531USD182
2023-04-01 to 2023-06-304,519,995USD91
2023-01-01 to 2023-06-309,868,513USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-04-01 to 2024-06-303,860,499USD91
2024-01-01 to 2024-06-308,027,786USD182
2023-04-01 to 2023-06-301,887,476USD91
2023-01-01 to 2023-06-304,541,029USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-06-306,993,406shares
At 2023-12-316,993,406shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-06-3030,981,000USD
At 2023-06-3051,896,711USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-16,802,292USD182
2023-01-01 to 2023-06-30-13,162,448USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-302,417,069USD91
2024-01-01 to 2024-06-304,931,745USD182
2023-04-01 to 2023-06-302,632,519USD91
2023-01-01 to 2023-06-305,327,484USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-976,975USD182
2023-01-01 to 2023-06-30-671,416USD181

Inspect the source

Entity
Minerva Neurosciences, Inc. / CIK 0001598646
Captured
SEC response SHA-256
7b57da641574943cc8f7ca81f9c94ea1ff7a872915407c01165fb2137ec7efc4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001598646.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))